MMD's Cardizem (diltiazem)
Marion Merrell Dow and its supplier of bulk diltiazem, Tanabe Seiyaku, file complaint with the International Trade Commission against at least eight foreign and U.S. firms MMD says have violated Tanabe's process patent for bulk diltiazem. Among the firms named in the complaint are Profarmaco Nobel, an Italian producer, and Mylan, its U.S. customer; Copley Pharmaceutical and its Finnish supplier Orion Corp. Fermion and ABIC Ltd., a subsidiary of Israeli firm Teva, which MMD says "supplies diltiazem to various companies." Rhone-Poulenc Rorer, which is already in litigation with MMD ("The Pink Sheet" Feb. 22, T&G-8) is also named in the ITC complaint.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth